The content on this site is intended for healthcare professionals only
Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
27 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
21 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
14 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
14 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
12 Sep 2022
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
12 Sep 2022
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-smal...
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
12 Sep 2022
Emerging systemic therapies in rare urothelial cancer variants
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürma...
11 Sep 2022
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squ...
Dr Silvia Novello - University of Turin, Turin, Italy
11 Sep 2022